Key Insights

Highlights

Treatment Research

1 treatments under study, led by Cetuximab Cisplatin Doxorubicin Cyclophosphamide

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01025089Phase 2Active Not Recruiting

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Showing all 1 trials

Research Network

Common Treatments

  • Cetuximab Cisplatin Doxorubicin Cyclophosphamide1

Active Sponsors

  • M.D. Anderson Cancer Center1
  • City of Hope National Medical Center1
  • Memorial Sloan Kettering Cancer Center1
  • Eli Lilly and Company1

Top Investigators

Related Conditions

  • Thymoma1
  • Thymic Carcinoma1

Activity Timeline